• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Timber Pharmaceuticals Inc.

    8/15/22 6:01:57 AM ET
    $TMBR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TMBR alert in real time by email
    SC 13G 1 ea164356-13gintra_timber.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    Timber Pharmaceuticals, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

     

    (Title of Class of Securities)

     

    887080109

     

    (CUSIP Number)

     

    August 4, 2022

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a. ☐ Rule 13d-1(b)
    b. ☒ Rule 13d-1(c)
    c. ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 8 

     

     

    CUSIP No. 887080109  

     

    1.

    Names of Reporting Persons.

     

    Mitchell P. Kopin

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b)

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States of America

    Number of
    Shares

    Beneficially

    Owned by

    Each
    Reporting Person
    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,763,596

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,763,596

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,763,596 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    4.2% (see Item 4)

    12.

    Type of Reporting Person (See Instructions)

     

    IN; HC

     

    Page 2 of 8 

     

     

    CUSIP No. 887080109  

     

    1.

    Names of Reporting Persons.

     

    Daniel B. Asher

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b)

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States of America

    Number of
    Shares

    Beneficially

    Owned by

    Each
    Reporting Person
    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,763,596

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,763,596

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,763,596 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    4.2% (see Item 4)

    12.

    Type of Reporting Person (See Instructions)

     

    IN; HC

     

    Page 3 of 8 

     

     

    CUSIP No. 887080109  

     

    1.

    Names of Reporting Persons.

     

    Intracoastal Capital LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b)

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of
    Shares

    Beneficially

    Owned by

    Each
    Reporting Person
    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,763,596

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,763,596

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,763,596 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    4.2% (see Item 4)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    Page 4 of 8 

     

     

    Item 1.

     

    (a) Name of Issuer

     

    Timber Pharmaceuticals, Inc. (the “Issuer”)

     

    (b) Address of Issuer’s Principal Executive Offices

     

    110 Allen Road, Suite 401

    Basking Ridge, NJ 07920

    Item 2.

     

    (a) Name of Person Filing

     

    (b) Address of Principal Business Office or, if none, Residence

     

    (c) Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended. 

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

     

    (d) Title of Class of Securities

     

    Common Stock, $0.001 par value per share, of the Issuer (the “Common Stock”).

     

    (e) CUSIP Number

     

    887080109

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Page 5 of 8 

     

     

    Item 4. Ownership.

     

    (a) and (b):

     

    (i) Immediately following the execution of the securities purchase agreement with the Issuer on August 4, 2022 (the “SPA”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on August 8, 2022), each of the Reporting Persons may have been deemed to have beneficial ownership of 7,080,051 shares of Common Stock, which consisted of (i) 4,166,667 shares of Common Stock to be issued to Intracoastal at the consummation of the transaction contemplated by the SPA and (ii) 2,913,384 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the consummation of the transaction contemplated by the SPA (“Intracoastal Warrant 1”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 63,791,336 shares of Common Stock outstanding prior to the execution of the SPA as reported to the Reporting Persons by the Issuer, plus (2) 4,166,667 shares of Common Stock to be issued to Intracoastal at the consummation of the transaction contemplated by the SPA and (3) 2,913,384 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 1,253,283 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock, (II) 1,562,500 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (III) 20,000 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 3”) because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (IV) 3,393 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal (“Intracoastal Warrant 4”) because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (V) 9,433 shares of Common Stock issuable upon exercise of a fourth warrant held by Intracoastal (“Intracoastal Warrant 5”) because Intracoastal Warrant 5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (VI) 1,603 shares of Common Stock issuable upon exercise of a fifth warrant held by Intracoastal (“Intracoastal Warrant 6”) because Intracoastal Warrant 6 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 6 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 9,930,263 shares of Common Stock. 

     

    (ii) As of the close of business on August 12, 2022, each of the Reporting Persons may have been deemed to have beneficial ownership of 5,763,596 shares of Common Stock, which consisted of (i) 4,166,667 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, (ii) 1,562,500 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, (iii) 20,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3, (iv) 3,393 shares of Common Stock issuable upon exercise of Intracoastal Warrant 4, (v) 9,433 shares of Common Stock issuable upon exercise of Intracoastal Warrant 5 and (iv) 1,603 shares of Common Stock issuable upon exercise of Intracoastal Warrant 6, and all such shares of Common Stock represented beneficial ownership of approximately 4.2% of the Common Stock, based on (1) 132,451,180 shares of Common Stock outstanding on August 9, 2022 as reported by the Issuer, plus (2) 4,166,667 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, (3) 1,562,500 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, (4) 20,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3, (5) 3,393 shares of Common Stock issuable upon exercise of Intracoastal Warrant 4, (6) 9,433 shares of Common Stock issuable upon exercise of Intracoastal Warrant 5 and (7) 1,603 shares of Common Stock issuable upon exercise of Intracoastal Warrant 6.

     

    (c) Number of shares as to which each Reporting Person has:

     

    (i) Sole power to vote or to direct the vote:        0       .

     

    (ii) Shared power to vote or to direct the vote:        5,763,596        .

     

    (iii) Sole power to dispose or to direct the disposition of        0       .

     

    (iv) Shared power to dispose or to direct the disposition of        5,763,596       .

     

    Page 6 of 8 

     

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 7 of 8 

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: August 15, 2022

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher

     

      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

     

    Page 8 of 8

     

    Get the next $TMBR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TMBR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TMBR
    Financials

    Live finance-specific insights

    See more
    • Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results

      - Lead asset TMB-001 is only compound to receive official orphan drug designation from European Commission for two severe subtypes of congenital ichthyosis, ARCI and XLRI - - Timber has enrolled 50% of patients for pivotal TMB-001 Phase 3 ASCEND clinical trial - WARREN, NJ, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the fourth quarter and year ended December 31, 2022. John Koconi

      3/31/23 4:28:34 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results

      -Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal Phase 3 ASCEND clinical trial continues to progress; expected to enroll more than 140 patients with moderate to severe Congenital Ichthyosis- BASKING RIDGE, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the third quarter of 2022, ended September 30, 2022. John Koconis, Chairman and Chie

      11/14/22 8:00:00 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results

      Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30th, 2022  BASKING RIDGE, NJ, May 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the first quarter of 2022, ended March 31, 2022. John Koconis, Chairman and Chief Executive Officer of Timber, commented, "Timber's lead asset, TMB-001, continues to progress following the receipt of Fast Track designation late last month, w

      5/12/22 4:10:00 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    Leadership Updates

    Live Leadership Updates

    See more
    • Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors

      LAVAL, Quebec, March 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST) today announces that it has appointed Michael L. Derby to its Board of Directors. "Michael is a successful pharma industry leader whose extensive involvement in drug repurposing and his passion for developing and commercializing innovative products that positively impact patients' lives will prove to be invaluable as we advance our three lead clinical assets," stated Dr. Roddy Carter, Chairman of the Board of Acasti. "We anticipate benefitting from his perspective and broad experience." Mr. Derby brings more than two decades of experience and a proven track record wit

      3/25/22 7:30:00 AM ET
      $ACST
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Announces Appointment of John Koconis as Chairman of the Board of Directors

      - Edward J. Sitar appointed as Lead Independent Director of the Board - - Company establishes Science and Technology Committee to be chaired by Dr. David Cohen - Basking Ridge, NJ, April 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that Chief Executive Officer John Koconis has been appointed as Chairman of the Board of Directors. The Company also announced that Edward J. Sitar has been appointed as Lead Independent Director of the Board and David Cohen, M.D., will

      4/23/21 8:00:00 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Appoints Alan Mendelsohn, M.D., as Chief Medical Officer

      Dr. Mendelsohn has 20+ Years’ Experience in Clinical Development and Medical Affairs WOODCLIFF LAKE, NJ, Jan. 25, 2021 (GLOBE NEWSWIRE) --   via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the appointment of Alan Mendelsohn, M.D., as Chief Medical Officer. Dr. Mendelsohn assumes the roles and responsibilities of Amir Tavakkol, Ph.D., who will be stepping down as the Company’s Chief Scientific Officer.  “We are pleased to welcome Dr. Mendelsohn to our management team. Dr. Mendelsohn

      1/25/21 4:05:00 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

      WARREN, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the staff of NYSE Regulation (the "NYSE Regulation") has determined to immediately suspend trading in the Company's common stock from NYSE American, LLC (the "NYSE American"). As previously disclosed, the NYSE Regulation notified Timber on November 21, 2023 that, as a result of the voluntary bankruptcy petitions filed under Chapter 11 of the United States Bankruptcy Code by the Company and certain of its

      11/29/23 5:26:24 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE American

      WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated debtors and debtor-in-possession ("Timber" or the "Company"), today announced that all "first day" motions related to the Company's voluntary Chapter 11 petitions for reorganization filed on November 17, 2023, were approved on an interim basis by the U.S. Bankruptcy Court for the District of Delaware. At the hearing, among other things, the Court approved an initial $3.0 million in interim funding pursuant to a debt

      11/28/23 5:21:07 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance

      WARREN, NJ, Sept. 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the NYSE American LLC (the "NYSE American") has accepted the Company's business plan to regain compliance with the continued listing standards set forth in Sections 1003(a)(i) and (ii) of the NYSE American Company Guide. As previously disclosed, on June 28, 2023, the Company received written notice from the NYSE American that the Company was not in compliance with Sections 1003(a)(i)

      9/18/23 4:05:00 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    SEC Filings

    See more
    • Timber Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

      1/26/24 8:00:46 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Bankruptcy or Receivership

      8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

      1/22/24 7:21:51 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

      12/22/23 4:12:24 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Timber Pharmaceuticals Inc.

      SC 13G - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

      8/15/22 6:01:57 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Timber Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

      2/14/22 9:40:54 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Timber Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

      2/4/22 3:39:18 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Koconis John was granted 70,385 shares, increasing direct ownership by 17,596% to 70,785 units

      4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

      8/22/23 7:46:54 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Mendelsohn Alan was granted 35,193 shares, increasing direct ownership by 17,596% to 35,393 units

      4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

      8/22/23 7:45:20 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Lucchese Joseph was granted 35,193 shares

      4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

      8/22/23 7:43:35 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care